The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2025 | Cilta-cel versus conventional treatment regimens in multiple myeloma: a real-world study
Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, discusses a recent real-world study that compared ciltacabtagene autoleucel (cilta-cel) with conventional treatment regimens at early relapse in multiple myeloma. The study found that the CAR-T therapy was superior in terms of disease control and survival, and Dr Fonseca believes that CAR-T will become a more prominent treatment option at first relapse. This interview took place at the 22nd International Myeloma Society (IMS) Annual Meeting in Toronto, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Speaking of real-world evidence publications, we had a recent one where we actually compared the use of cilta-cel in early relapse versus the use of other regimens which have not been represented in clinical trials, but up until recently were considered the standard of care or the best available, including regimens that have carfilzomib as part of that combination. So regimens like CANDOR and IKEMA...
Speaking of real-world evidence publications, we had a recent one where we actually compared the use of cilta-cel in early relapse versus the use of other regimens which have not been represented in clinical trials, but up until recently were considered the standard of care or the best available, including regimens that have carfilzomib as part of that combination. So regimens like CANDOR and IKEMA. And what we have found is when you actually do a direct comparison of the duration of disease control and the survival for patients being treated with a CAR-T approach, cilta-cel specifically, versus those that get regimens like DKB, we still come out greatly in favor for the cell-based therapies. I myself believe that as we better understand how to manage some of the toxicities associated with these therapeutics, more and more we’re going to be proposing that at the first relapse CAR-T’s are used for the treatment of myeloma patients. And this is a little bit more of evidence in that regard.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Consulting: AbbVie, Adaptive, Amgen, Apple, BMS/Celgene, GSK, Janssen, Karyopharm, Pfizer, RA Capital, Regeneron, Sanofi. Scientific Advisory Board: Caris Life Sciences Board of Directors: Antengene Patent for FISH in MM.
